This section considers submissions that focus on all areas of clinical pharmacology including rational prescribing, pharmacoeconomics, pharmacovigillance, pharmacoepidemiology and clinical trials.
1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function
The indoleamine 2, 3-dioxygenase (IDO) inhibitor 1-methyl-tryptophan (1-MT) is currently being used in clinical trials in patients with relapsed or refractory solid tumors by inhibiting tumor immune escape. A ...
Citation: BMC Pharmacology and Toxicology 2020 21:67